Participants are randomly assigned to either continue both the pill and the biologic or to stop the pill after a short period. If disease activity rises (a flare), the stopped medication can be started again. All participants keep receiving their regular biologic injections. The study follows each person for up to two years, with clinic visits scheduled at about 3, 6, 12, 18 and 24 months.

At each visit, doctors will check how active the disease is using a score called DAS28-CRP, ask about pain, fatigue and daily function, and record any side effects. Patients will also fill out questionnaires about quality of life and work ability. Blood samples may be taken to measure drug levels. The study aims to compare overall disease control, safety and cost between the two approaches.

People in the study are assigned by chance to receive different doses of ELV001 or placebo tablets. The study is double-blind, which means that the treatment given is not known to the participants or the study team during the study. Treatment is taken for a period of time, and the health of the joints and overall condition are checked during the study visits. Safety is also watched closely, including possible side effects and changes in heart tracing, blood tests, and vital signs.

The study is looking at whether ELV001 can improve signs and symptoms of active rheumatoid arthritis when added to standard treatment. It also compares different dose levels to see how they work and how well they are tolerated.

The main aim of the study is to evaluate the long‑term safety and tolerability of the medication. After a previous trial, participants may continue receiving the study drug or placebo for an extended period, with regular clinic visits where health status is checked, blood samples are taken, and any side effects are recorded.

During the study, doctors will look for improvements in joint symptoms and overall disease activity using standard assessment tools, and they will monitor laboratory results and vital signs to ensure the medication remains safe over time.

The purpose of this study is to assess the safety of cizutamig in patients with these severe inflammatory conditions and to examine how well the treatment works in controlling disease activity. During the study, patients will receive the medication and will be closely monitored for any side effects, particularly Cytokine Release Syndrome and other treatment-related reactions. The study will track various measures of disease activity specific to each condition, such as skin thickness scores for systemic sclerosis, muscle strength measurements for inflammatory myopathy, disease activity scores for rheumatoid arthritis, and symptom scores for Sjögren’s disease. For patients who have lung involvement, lung function tests will also be performed.

The study will last approximately 52 weeks, with regular assessments at different time points to evaluate both the safety and effectiveness of the treatment. Patients will have measurements taken at weeks 16, 24, and 52 to see how their disease responds to cizutamig. The study will also look at whether patients can reduce or stop other medications they may be taking, how often their disease flares up, and how their overall quality of life and daily functioning change during the treatment period.

The purpose of this study is to find out whether combining these two different biologic medications is safe and whether it works better at controlling disease activity than current treatments alone. The study will specifically measure how many patients achieve remission, which means their disease becomes much less active or shows minimal signs of inflammation. The researchers want to test whether blocking two different inflammation pathways at the same time can help more patients reach this state of very low disease activity.

During the study, patients will receive the combination treatment for a period of time while their disease activity is regularly monitored. The main assessment will take place at week 24 to see how well the combination therapy has worked. Throughout the study, doctors will also carefully watch for any side effects or safety concerns that might occur when using these two medications together. The study will collect information about how well patients tolerate the combination treatment and whether their symptoms improve according to standard measurement tools used to assess arthritis activity.

Participants will receive QEL-005 through an intravenous infusion, which is a method of delivering the medicine directly into a vein. The study is conducted in stages to monitor how the body reacts to the treatment. During this process, health professionals will monitor for any side effects or changes in vital signs and electrocardiogram, a test that records the electrical activity of the heart, to ensure the safety of the procedure.

During the study, participants will receive either AZD1163 or a placebo through a subcutaneous injection, which is a method of delivering medicine into the fatty tissue just below the skin. This is a double-blind study, meaning that neither the participants nor the researchers will know which specific treatment is being administered until the study is completed. Participants will be divided into different groups to compare the effects of the active drug against the inactive substance.

The purpose of the study is to evaluate whether a specific dosing method, known as dose-banding, is as effective as dosing based on a person’s body weight. During the study, participants will receive tocilizumab through regular infusions. The activity of the disease will be monitored using a tool called the DAS28, which is a score used by healthcare professionals to measure how much inflammation and joint damage is present. This process will be followed over a period of several months to observe any changes in the condition.

The purpose of the study is to evaluate the long-term safety of KYV-101. Participants will be monitored over an extended period to observe how the body reacts to the medication over time. This involves checking for the development of new health issues, such as malignancy, which refers to cancerous growths, or any changes in existing neurologic conditions, which are related to the brain and nervous system. The study also tracks changes in rheumatologic issues, which involve the joints and connective tissues, or hematologic disorders, which are conditions affecting the blood.

During the trial, participants will be assigned to receive either rituximab or a placebo. The study will last for 48 weeks. While receiving the assigned treatment, the progress of the lung condition and the effectiveness of the medication will be monitored to see if it helps prevent the decline of the amount of air the lungs can hold.

The purpose of this study is to measure how much of the medicine gets into the bloodstream when the capsule is opened and sprinkled on applesauce, strawberry jam, or yoghurt compared to swallowing the capsule whole without food, and also to see how eating food affects the amount of medicine that gets into the bloodstream when the capsule is swallowed whole. This information is important for understanding different ways the medicine can be taken, especially for people who may have difficulty swallowing capsules. The study will involve healthy adult participants who will receive a 30 mg dose of the medicine in different ways during the study.

Participants will take part in a study where they will receive the medicine in different forms on different occasions, allowing researchers to compare how the body processes the medicine under various conditions. Blood samples will be collected to measure the amount of medicine in the bloodstream over time. The study will monitor participants for any unwanted effects that may occur during the treatment period.

The purpose of this study is to see if SPY072 can reduce disease activity in people with these three types of rheumatologic disease and to check if the medication is safe. The study will measure how well SPY072 works by looking at different aspects of disease activity. For rheumatoid arthritis, the study will check changes in disease activity at week 12. For axial spondyloarthritis and psoriatic arthritis, measurements will be taken at week 16. The study will also look at how many participants show improvement in their symptoms and will measure the levels of the medication in the blood.

During the study, participants will receive treatment for up to 40 weeks. The study will monitor participants for any unwanted effects or problems that might occur with the medication. The study will also check if the body develops any immune response to the medication. Different measurements will be used depending on which type of rheumatologic disease the participant has, but all are designed to see if the medication helps reduce joint pain, swelling, and other symptoms of the disease.

The medication tulisokibart will be given as an injection under the skin using a pre-filled device that automatically delivers the medicine. The study will last for about 128 weeks in total. During this time, doctors will check how well the treatment is working by looking at improvements in joint pain, swelling, and other symptoms of the disease. They will also monitor participants for any unwanted effects that may occur during treatment.

The study will measure whether participants achieve certain levels of improvement in their condition, including 20%, 50%, or 70% improvement according to standard measures used for rheumatoid arthritis. Doctors will also assess whether participants reach a state of low disease activity and whether their ability to perform daily activities improves. Throughout the study, any side effects or problems that participants experience will be carefully recorded and reviewed.

The study aims to examine how specific immune cells called B cells respond to the tetanus vaccine in people with autoimmune diseases. Participants will receive a single booster shot of the tetanus vaccine as a suspension for injection into the muscle. The amount given will be 0.5 milliliters, which is a standard vaccine dose.

During the study, researchers will collect blood samples at different times to observe how the immune system responds to the vaccine. They will look at special immune cells and proteins in the blood before and after vaccination. This will help them understand the differences between how the immune system works in people with autoimmune diseases compared to people without these conditions.

The study aims to determine if SAR441566 combined with methotrexate works better than placebo with methotrexate in treating moderate to severe rheumatoid arthritis. The treatment will be given as tablets taken by mouth. The study will last for 12 weeks, during which participants will receive either the study medication or placebo along with their regular methotrexate treatment.

Throughout the study, doctors will monitor how well the treatment works and check for any side effects. They will measure improvements in joint symptoms and overall disease activity. Blood samples will be collected to measure the amount of study medication in the body. This research is conducted as a phase 2 study, which means it is part of the early stages of testing this new treatment.

Before receiving the main treatment, patients will undergo preparation with two medications: cyclophosphamide and fludarabine, which help reduce certain immune cells in the body. The purpose of this study is to determine if this combination treatment is safe and if it can help improve symptoms in patients with these hard-to-treat rheumatic conditions.

The treatment involves receiving the medications through intravenous infusion (delivery directly into a vein). Patients will receive multiple doses of the study medications over several weeks and will be monitored regularly to check how well the treatment works and to watch for any side effects. The study will track various measurements of disease activity and symptoms specific to each condition to determine if the treatment is effective.

The purpose of this research is to determine if gradually reducing the dose of these medications is as effective as continuing with the current dose in patients whose disease is well-controlled. The study will examine patients who have maintained low disease activity or whose symptoms have been in remission for at least 6 months while taking these medications.

During the 12-month study period, participants will be monitored for disease activity, quality of life, and any side effects. The study will track how well the joints function, any disease flare-ups, and other health-related factors. Researchers will also measure medication levels in the blood and examine immune system cells to better understand how these treatments work.

The purpose of this research is to evaluate how safe and effective these medications are in treating moderate to severe rheumatoid arthritis, either when used alone or in combination. The medications will be tested in patients who have previously tried other treatments for their condition but still have active disease symptoms.

During the study, participants will receive their assigned treatment for 12 months. All patients will continue taking methotrexate, a standard medication for rheumatoid arthritis, throughout the study period. The study will monitor how well the treatments work by measuring improvements in joint symptoms and overall disease activity.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

During the study, participants with active arthritis who are currently using TNF inhibitors will receive a combination therapy approach. The research will monitor how well this combination works to reduce disease activity and inflammation in the joints. The main goal is to see if patients can achieve remission, which means having very low or no disease activity after 24 weeks of treatment.

The study will also collect information about the safety and tolerability of combining these medications. This approach using multiple medications together is being investigated as a potential way to improve outcomes for patients whose arthritis symptoms aren’t adequately controlled with current therapies.

The medication CIT-013 will be tested at various dose levels (including 50 mg and 100 mg) to determine if it can reduce disease activity. Participants in this study will continue taking their conventional synthetic disease modifying antirheumatic drug (a medication that slows the progression of rheumatoid arthritis) that they were on before joining the study.

The trial will follow participants for approximately 85 days to monitor how the medication affects their disease activity score (a measurement of arthritis symptoms and inflammation). Throughout the study, researchers will assess joint tenderness, joint swelling, and other indicators of disease activity, as well as monitor participants for any side effects that may occur.

The purpose of the study is to investigate the effect of Janus Kinase inhibitors on heart function, heart muscle inflammation, and the structure of coronary arteries in patients with Rheumatoid Arthritis. Participants will be given Jyseleca in the form of film-coated tablets, taken orally. The study will compare heart health before and after one year of treatment with this medication. Some participants will receive a placebo for comparison.

Throughout the study, participants will undergo various assessments to monitor changes in heart function and overall health. These assessments will help researchers understand the potential benefits and risks of using filgotinib for treating Rheumatoid Arthritis, particularly in relation to heart health. The study is expected to continue until early 2026, providing valuable insights into the treatment of this condition.

Participants in the study will receive either the new treatment, IMVT-1402, or a placebo, which looks like the treatment but contains no active substance. The study will be conducted in two periods. During the first period, all participants will receive the treatment. In the second period, some participants will continue with the treatment, while others will receive the placebo. The study will last for several weeks, and participants will be monitored to see how their symptoms change over time.

The main goal is to see how many participants maintain a positive response to the treatment by the end of the study. Additionally, changes in specific scores that measure disease activity will be observed. This study aims to provide more information about the potential benefits and safety of IMVT-1402 for people living with rheumatoid arthritis.

The purpose of the study is to assess the safety of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis and severe, refractory Sjögren’s disease with organ involvement. Participants will receive the treatment through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will also involve monitoring the behavior of the treatment in the body, known as cellular kinetics, to understand how it moves and changes over time.

In addition to rapcabtagene autoleucel, the study will also involve the use of other medications, including tocilizumab, fludarabine phosphate, and cyclophosphamide. These medications are commonly used in treating autoimmune diseases and will be administered as part of the study protocol. Some participants may receive a placebo instead of the active treatment. The study aims to gather information over a period of time to evaluate the treatment’s safety and its potential effectiveness in managing these complex diseases.

Participants in the study will receive Rituximab through an infusion, which means the medication is delivered directly into the bloodstream. The study will last for about a year, during which the participants’ disease activity will be monitored at the start, at six months, and at the end of the study. This will help determine if the lower dose of Rituximab can maintain the same level of disease control as the higher dose.

The goal of the study is to find out if using a smaller amount of Rituximab can still effectively manage Rheumatoid Arthritis without increasing the disease activity. This could potentially lead to fewer side effects and a more convenient treatment option for patients. The study will also track any changes in the participants’ health and any side effects they may experience during the trial period.

The medication being studied is RoActemra, which contains tocilizumab and comes in the form of a solution for injection in pre-filled syringes. Each injection contains 162 mg of the medicine, which is administered through subcutaneous injection (under the skin). The purpose of this study is to evaluate how bone erosions change in size and depth when patients are treated with this medication.

During the study, detailed images of the bones in patients’ hands will be taken using special scanning techniques to measure changes in bone damage. The study will also look at other effects of the treatment, including changes in bone density and structure, as well as how well the treatment controls the symptoms of rheumatoid arthritis.

The purpose of the study is to determine if the treatment with Filgotinib is not worse than, and possibly better than, the treatment with triamcinolone acetonide when both are used alongside standard therapies like methotrexate and hydroxychloroquine. Participants will be monitored over a period of time to assess their disease activity and overall health. The study will track how many patients achieve remission at three months and will also look at other factors such as patient satisfaction, side effects, and the overall use of medications during the study.

Throughout the study, participants will have regular check-ups to monitor their progress and any changes in their condition. The study aims to provide valuable information on the effectiveness of these treatments in managing rheumatoid arthritis, potentially leading to improved care for patients with this condition.

Participants in the study will be randomly assigned to one of two groups. One group will continue receiving the standard dose of Tocilizumab, while the other group will have their dosing interval increased to every two weeks. The study will last for a total of 52 weeks, during which the participants’ disease activity will be monitored. This will help determine if the adjusted dosing is as effective as the regular dosing in managing the symptoms of Rheumatoid Arthritis.

Throughout the study, various aspects will be observed, such as the difference in disease activity scores, the number of flare-ups, and any side effects experienced by participants. Additionally, the study will look at the cost differences between the two dosing methods and gather feedback from participants about their experience with the adjusted dosing. The goal is to find the most effective and efficient way to use Tocilizumab in treating Rheumatoid Arthritis.

Participants in the study will receive either CT-P13 or a placebo over a period of time. The study will monitor the participants’ response to the treatment, specifically looking for a 20% improvement in their symptoms by the 12th week, as defined by the American College of Rheumatology (ACR). This improvement is known as the ACR20 response. The study will also involve other medications that are commonly used to manage rheumatoid arthritis, such as methotrexate, ibuprofen, paracetamol, hydroxychloroquine, hydrocortisone, and folic acid. These medications help reduce inflammation, relieve pain, and support overall health during the trial.

The trial is designed to last for several weeks, during which participants will be closely monitored by healthcare professionals. The goal is to determine if CT-P13 is more effective than the placebo in improving the symptoms of rheumatoid arthritis, providing valuable information for future treatment options. Participants will receive regular check-ups and assessments to ensure their safety and to track the progress of their condition throughout the study.

The purpose of the study is to see if certain markers in the body, known as CD80/CD86 biomarkers, can predict how well patients with early rheumatoid arthritis will respond to treatment with abatacept. Participants in the study will receive either the active medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 16 weeks, during which participants will receive regular injections and attend scheduled visits to monitor their progress.

Throughout the study, researchers will assess changes in the participants’ condition using various measures, such as the Disease Activity Score and the American College of Rheumatology criteria. These assessments will help determine the effectiveness of the treatment in reducing symptoms and improving the quality of life for those with rheumatoid arthritis. The study aims to provide valuable insights into personalized treatment approaches for this condition.

The purpose of the study is to see if changes in the PET-CT images after four weeks of treatment can predict how well patients will respond to the therapy after 26 weeks. The study will also look at changes in the joint tissue to understand more about how the treatment works, especially focusing on certain cells called macrophages and a protein known as FRβ.

Participants in the study will receive the [18F]Fluor-PEG-Folate solution through an intravenous infusion, which means it will be injected into a vein. The study will follow patients over a period of time to observe the effects of the treatment and the changes in their condition. Some participants may receive a placebo, which is a substance with no active medication, to compare the results. The study aims to provide valuable insights into the effectiveness of anti-TNF therapy for people with rheumatoid arthritis.

The purpose of the study is to evaluate how well this medication can show inflammation in the arteries and joints of patients who have recently been diagnosed with Giant Cell Arteritis or have active Rheumatoid Arthritis. Participants will receive the medication through an intravenous (IV) injection, which means it will be administered directly into a vein. After receiving the medication, participants will undergo a PET/CT scan to capture images of their arteries and joints. This will help researchers understand how the medication is taken up in these areas and how it can be used to assess inflammation.

The study will follow participants over a period of time to monitor the uptake of the medication in their bodies. The main focus will be on measuring how much of the medication is absorbed in different arteries or joints, which is expressed in terms of standardized uptake values (SUVs). This information will help determine the effectiveness of the medication in highlighting inflamed areas, potentially leading to better diagnosis and treatment options for these conditions in the future.

The purpose of the study is to evaluate how sarilumab affects the body, particularly looking at changes in joint inflammation and gene activity. Participants will receive Kevzara as a solution for injection under the skin. The study will last for 24 weeks, during which time participants will undergo various assessments, including MRI scans to monitor joint health and synovial tissue analysis, which involves examining the tissue lining the joints.

Throughout the study, researchers will collect data to understand the medication’s impact on joint inflammation and overall disease activity. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of sarilumab. The study aims to provide insights into how sarilumab can benefit patients with rheumatoid arthritis who have not found relief with other treatments.

The purpose of this study is to determine if MB04 works as effectively as Enbrel in treating rheumatoid arthritis. Both medications are given as injections under the skin using pre-filled syringes. During the study, patients will also continue taking methotrexate, which is a standard medication for rheumatoid arthritis treatment.

The treatment period lasts 36 weeks, during which patients receive injections of either MB04 or Enbrel. The maximum daily dose is 50 mg, and the total amount of medication received during the study will not exceed 1800 mg. Throughout the study, doctors will monitor how well the medications work by checking joint symptoms and overall disease activity.

Participants in the study will be randomly assigned to receive either spironolactone or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The medication will be taken orally in the form of a film-coated tablet. The study will last for a total of six months, with regular check-ups to monitor the participants’ health and the effects of the treatment.

Throughout the study, various health parameters will be assessed, including the level of rheumatoid arthritis activity and any potential side effects. The goal is to determine if spironolactone can help reduce the symptoms of rheumatoid arthritis and improve the quality of life for those affected by this condition. Participants will be closely monitored to ensure their safety and well-being during the trial.

Participants in the study will receive ianalumab through subcutaneous injections, which means the medication is administered under the skin. The study will take place over a period of time, allowing researchers to observe how the medication is absorbed and processed by the body. The goal is to ensure that the different forms of administering ianalumab are equally effective and safe for patients. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of ianalumab.

In addition to ianalumab, the study will also involve other medications such as emtricitabine, tenofovir disoproxil, tenofovir alafenamide, and entecavir, which are typically used to manage viral infections. These medications will be administered orally, meaning they are taken by mouth. The study will monitor various health indicators, including any side effects, to ensure the safety and effectiveness of the treatments. The overall purpose is to gather information that could lead to better treatment options for people with these autoimmune diseases.

Participants in the study will continue their current treatment with adalimumab and methotrexate (MTX), a common medication used to treat rheumatoid arthritis. The study will involve gradually spacing out the adalimumab injections based on regular assessments every three months. These assessments will help determine the lowest effective dose needed to maintain remission. The study aims to find the minimal necessary concentration of adalimumab in the blood to keep the disease in check.

Throughout the study, the presence of antibodies against adalimumab will be monitored, as these can affect how well the medication works. Participants will also be asked to report any infections they experience, as this information is important for understanding the safety of the treatment. The study is expected to continue until mid-2026, with recruitment starting in late 2024.

The purpose of the study is to compare the effectiveness of taking tofacitinib either in the morning or in the evening. Participants will be randomly assigned to take the medication at one of these times. The study will last for about three months, during which participants will report on their disease activity, which refers to how active their arthritis symptoms are. The study will also look at other factors like morning stiffness, general health, fatigue, pain, sleep, and quality of life.

Researchers will also explore whether changes in certain genes related to the body’s internal clock, known as circadian clock genes, and the composition of bacteria in the gut, called microbiota, are linked to how well the treatment works. This study aims to provide insights into the best time of day to take tofacitinib for managing symptoms of rheumatoid arthritis and psoriatic arthritis.

The trial will involve several medications, including Methotrexate, Simponi (containing golimumab), Hydroxychloroquine sulfate, Cimzia (containing certolizumab pegol), Depo-Medrol (containing methylprednisolone acetate), Leflunomide, Enbrel (containing etanercept), Humira (containing adalimumab), Sulfasalazine, Jyseleca (containing filgotinib), Kenacort-A (containing triamcinolone acetonide), and Remicade (containing infliximab). Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

Participants in the study will be randomly assigned to either the personalized treatment group or the usual care group. The study will last for several months, during which patients will receive their assigned treatments and have their disease activity monitored regularly. The effectiveness of the treatments will be assessed by measuring how well the disease is controlled and the overall cost-effectiveness of the treatment approaches. The study aims to provide insights into whether a personalized approach can improve outcomes for patients with rheumatoid arthritis.

The purpose of the study is to assess the safety of these treatments in patients with active and treatment-resistant Rheumatoid Arthritis. Participants will receive either Rituximab or KYV-101 and will be monitored over time to see how their condition responds to the treatment. The study will also look at changes in specific antibodies in the blood, which are proteins that the immune system uses to fight off perceived threats.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on how these treatments can help manage Rheumatoid Arthritis and improve the quality of life for those affected by this condition. Participants will be observed for any side effects and changes in their symptoms to ensure the treatments are safe and effective.